Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042
Press release content from Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 2 - Lead Compound News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lead Compound. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lead Compound Today - Breaking & Trending Today
Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042
Press release content from Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
DENR, EcoWaste renew call to ban lead paint
DENR, EcoWaste renew call to ban lead paint
Source: sunstar.com.ph
PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial
May 06, 2021 published at 7:30 AMglobenewswire PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial GlobeNewswire May 06, 2021 BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4 th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena G...
Source: asiaone.com
PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial | Comunicados | Edición USA
6 may 2021 PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4 th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d'Hebron in Barcelona...
Source: efe.com